Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Bioentrepreneur
  • Published:

How much risk are you prepared to take?

Nature Biotechnology volume 30, pages 821–824 (2012)Cite this article

Subjects

Any faculty member wishing to commercialize a discovery or technology should contemplate the pros and cons of pursuing the entrepreneurial route or licensing to an outside entity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Mark Van Dyke (formerly of Wake Forest University School of Medicine) is currently an Associate Professor at Virginia Polytechnic Institute and State University in Blacksburg, Virginia, USA, and CSO at KeraNetics LLC, Winston Salem, North Carolina, USA.,

    Mark Van Dyke

Authors
  1. Mark Van Dyke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Van Dyke.

Ethics declarations

Competing interests

M.V.D. is a founder, director, board member and shareholder in KeraNetics LLC, a company tasked with commercializing keratin biomaterial products.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Van Dyke, M. How much risk are you prepared to take?. Nat Biotechnol 30, 821–824 (2012). https://doi.org/10.1038/nbt.2330

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2330

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research